Posted by jrbecker76 on August 19, 2014, at 11:16:01
In reply to Re: LY2140023.For Schizophrenia., posted by Lamdage22 on August 15, 2014, at 13:57:04
> Again, check out "see also"
Unfortunately, this drug (aka Pomaglumetad methionil) failed to find significant findings in Ph III trials and is more than likely abandoned. There actually was some interesting data from the trial that showed that a subgroup of patients with a particular genotypic biomarker for the 5-HT2a receptor did particularly well with it. But I'm not sure Lilly is still pursuing it. They might still be looking at this class for Bipolar d/o though.
poster:jrbecker76
thread:1069838
URL: http://www.dr-bob.org/babble/20140815/msgs/1070008.html